Vaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average – Here’s Why

Vaxart, Inc. (NASDAQ:VXRT) shares passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.72 and traded as low as $0.51. Vaxart shares last traded at $0.52, with a volume of 1,118,684 shares traded.

Vaxart Stock Performance

The firm has a market cap of $122.63 million, a price-to-earnings ratio of -1.31 and a beta of 1.69. The business has a fifty day moving average of $0.67 and a two-hundred day moving average of $0.72.

Institutional Investors Weigh In On Vaxart

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE lifted its stake in Vaxart by 10.8% in the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 17,942 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Vaxart by 48.6% during the 4th quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 24,803 shares during the period. Graham Capital Management L.P. lifted its stake in shares of Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 32,482 shares during the period. Sequoia Financial Advisors LLC lifted its stake in shares of Vaxart by 140.9% during the 4th quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 35,213 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Vaxart by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock worth $1,723,000 after purchasing an additional 57,911 shares during the period. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.